发明名称 Anti-glypican-3 antibody
摘要 An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
申请公布号 US9102739(B2) 申请公布日期 2015.08.11
申请号 US200612089957 申请日期 2006.10.11
申请人 Chugai Seiyaku Kabushiki Kaisha;Xencor, Inc. 发明人 Lazar Gregory Alan;Dahiyat Bassil I.;Okabe Hisafumi;Sugimoto Masamichi;Iijima Shigeyuki;Sugo Izumi
分类号 C07K16/00;C12P21/08;C12P21/06;A61K39/395;A61K39/40;C07K16/30;C07K1/00;A61K39/00 主分类号 C07K16/00
代理机构 Fish & Richardson P.C. 代理人 Fish & Richardson P.C.
主权项 1. An anti-glypican-3 antibody comprising an Fc region having aspartic acid at EU numbering position 239, threonine at EU numbering position 326, alanine at EU numbering position 330, and glutamic acid at EU numbering position 332 of the Fc region, wherein the anti-glypican-3 antibody comprises a H-chain CDR1 as set forth in SEQ ID NO:23, a H-chain CDR2 as set forth in SEQ ID NO:24, and a H-chain CDR3 as set forth in SEQ ID NO:25, and comprises a L-chain CDR1 as set forth in SEQ ID NO:26, a L-chain CDR2 as set forth in SEQ ID NO:27, and a L-chain CDR3 as set forth in SEQ ID NO:28.
地址 Tokyo JP
您可能感兴趣的专利